FDA puts partial hold on BioNTech-OncoC4 phase 3 trial
21 hours ago · The FDA has implemented a partial hold on a phase 3 non-small cell lung cancer trial run by BioNTech and OncoC4 after seeing varying results among patients. The hold impacts an open-label trial ...
BioNTech and OncoC4 Announce Strategic Collaboration to Co …
Mar 20, 2023 · BioNTech and OncoC4 will jointly develop ONC-392 as monotherapy and in combination with anti-PD- (L)-1 antibodies in a range of solid tumor indications, including NSCLC, until approval, with the parties equally sharing development costs for such studies.
BioNTech and OncoC4 Present Positive Phase 1/2 Data for
Jun 2, 2023 · MAINZ, Germany, and ROCKVILLE, Maryland, USA, June 2, 2023 (GLOBE NEWSWIRE) — BioNTech SE (Nasdaq: BNTX, “BioNTech”) and OncoC4, Inc. (“OncoC4”), today announced positive preliminary data...
BioNTech and OncoC4 Initiate Pivotal Phase 3 Trial of …
Jun 29, 2023 · Initiation of pivotal Phase 3 trial in non-small cell lung cancer (NSCLC) marks the first landmark in BioNTech’s and OncoC4’s strategic collaboration initiated in March 2023 with the aim to evaluate BNT316/ONC-392 in various solid tumor indications
BioNTech's OncoC4 partnership off to good start with mid-stage …
Jun 2, 2023 · BioNTech said on Friday that a new cancer immunotherapy candidate that it is working on with U.S. partner OncoC4 Inc was shown to shrink tumours in close to 30% of participants in a mid-stage...
OncoC4 Announces First Patient with Advanced Prostate Cancer …
Feb 22, 2024 · BNT316/ONC-392 (gotistobart) is a next-generation anti-CTLA-4 antibody candidate jointly developed by BioNTech and OncoC4. BNT316/ONC-392 is currently in late-stage clinical development as monotherapy or combination therapy in various cancer indications.
OncoC4 and AcroImmune Announce Merger
Gotistobart (BNT316/ONC392) is a next-generation anti-CTLA-4 antibody candidate in joint late-stage clinical development with BioNTech as a monotherapy and in combination in multiple ongoing solid tumor indications. Designed for improved toxicity and ability to overcome immune suppression in the tumor microenvironment by depleting regulatory T ...
BioNTech and OncoC4 Announce Strategic Collaboration to Co …
Mar 20, 2023 · BioNTech and OncoC4 will co-develop ONC-392 as monotherapy or in combination with anti-PD1 in various solid tumor indications, with a randomized Phase 3 trial planned to start in 2023.
BioNTech shares slip as FDA places partial clinical hold on lung …
23 hours ago · Investing.com -- BioNTech (NASDAQ:BNTX) shares fell Friday after the company said it had been informed by partner OncoC4 that FDA placed partial clinical hold on Phase 3 study of BNT316/ONC-392 ...
BioNTech licenses solid tumor candidate from OncoC4 - Seeking Alpha
Mar 20, 2023 · BioNTech (NASDAQ: BNTX) announced an exclusive license and collaboration agreement with Rockville, Maryland-based biopharma OncoC4 on Monday to jointly develop and commercialize the latter’s...
- Some results have been removed